Anti-obesity agents: a focused review on the structural classification of therapeutic entities.

  title={Anti-obesity agents: a focused review on the structural classification of therapeutic entities.},
  author={Sangmi Oh and Koon Soon Kim and Young Sun Chung and Minho Shong and Seung Bum Park},
  journal={Current topics in medicinal chemistry},
  volume={9 6},
In addition to its enormous impacts on an individual's quality of life, obesity is a daunting health problem in the world today and the increasing rate of obesity is now causing a severe burden on health care systems. Fortunately, the normalization or reduction of increased body fat reverses the obesity-associated morbidities, such as hypertension, glucose intolerance, dyslipidemia, and fatty liver diseases. However, the modification of lifestyle in a case of established clinical obesity is… 

Tables from this paper

The Multifunctional Role of Herbal Products in the Management of Diabetes and Obesity: A Comprehensive Review

An examination of plant-inferred compounds that might be utilized against heftiness or potentially hostile to diabetes treatments and an expanded comprehension of the systems of activity of phytogenic compounds could prompt the advancement of remedial methodologies for metabolic diseases.

A Critical Review on Obesity: Herbal Approach, Bioactive Compounds, and Their Mechanism

The herbal approach, bioactive compounds, and their mechanism for treating obesity are discussed, including dry mouth and sleeping disorders, dizziness, blood pressure, heart rate elevation, constipation, and headache.

A review on the current drugs and new targets for obesity

The current drugs in the market used to treat obesity and also few of the new probable targets to discover drugs are reviewed.

Induction of NAFLD with Increased Risk of Obesity and Chronic Diseases in Developed Countries

The use of anti-obese drugs that reduce food intake and improve hypercholesterolemia and cardiovascular disease has been assessed in obesity with drug therapy closely involved either in the prevention or induction of NAFLD and obesity in man.

Identification of a New Chemotype of Anti-Obesity Compounds by Ensemble Screening

The VS process identified six compounds of different classes with enhanced inhibitory activities against lipid accumulation and without toxicity that resulted in weight loss and improved the fatty liver condition of mice with overnutrition in animal experiments.

Oral administration of Rehmannia glutinosa extract for obesity treatment via adiposity and fatty acid binding protein expression in obese rats

Oral RGE administration prevented weight gain and hyperlipidemia induced by long-term HFD feeding, presumably via a mechanism that inhibits the intestinal absorption of dietary fat by RGE.

Natural Product‐Based Drug Discovery

Interest in natural products and drug-delivery systems based on these materials has gained much importance during recent years and the quest for new drugs has begun to benefit from ethnopharmacological and/or local health traditions.

Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options

This review will focus on approved obesity medications, as well as potential new pharmacologic treatment options, which could help to achieve weight loss.

The Physiological Alterations Induced by Sibutramine Anti-Obesity Drug on the Functions of the Thyroid Gland and the Liver: An Experimental Study on Wistar Rats

It can be concluded that the long use of Sibutramine is not therapeutically safe and should not be prescribed at all for any patient who has a history of hormonal or liver disorders.



Pharmacological treatment of obesity: therapeutic strategies.

The present state of research in the field of therapeutics targeted for obesity is summarized, including promising new approaches for the future, as well as an increasing awareness of the public health risks associated with excess weight.

New agents in development for the management of obesity

The efficacy and pharmacology of the anti‐obesity agents currently used in clinical practice as well as some of the potential agents in phase II and III trials are reviewed.

The obesity epidemic: current and future pharmacological treatments.

The efficacy of antiobesity agents and their value in the treatment of obesity are assessed in comparison with other therapeutic approaches, such as surgery and changes in lifestyle.

Anti-obesity therapies

Obesity has long been associated with serious health issues, but has only recently been regarded as a disease in the sense of being a specific target for medical therapy.

New targets for obesity pharmacotherapy – developing anti‐obesity drugs that do not necessarily produce weight loss

It is not axiomatic that weight loss is a reliable marker for these treatment goals, but better knowledge of these factors could allow the development of drugs that protect rather than ‘cure’ the individual from obesity.

Strategies and potential molecular targets for obesity treatment.

Characterization of obesity-associated gene products has revealed new biochemical pathways and molecular targets for pharmacological intervention that will likely lead to new treatments that will be viewed as adjuncts to behavioral and lifestyle changes aimed at maintenance of weight loss and improved health.

Obesity as a medical problem

The global epidemic of obesity results from a combination of genetic susceptibility, increased availability of high-energy foods and decreased requirement for physical activity in modern society, and should be regarded as an epidemic that threatens global well being.

Adipokines and Insulin Resistance

Current data on the effect of the adipose tissue-derived hormones adiponectin, chemerin, leptin, omentin, resistin, retinol binding protein 4, tumor necrosis factor-α and interleukin-6, vaspin, and visfatin on insulin resistance are summarized.

Medicinal strategies in the treatment of obesity

For a drug to have significant impact on body weight it must ultimately reduce energy intake, increase energy expenditure, or both.

Adiponectin: an update.